https://www.aigom.it/wp-content/uploads/2026/02/ART24.2.png1059700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-24 07:47:032026-02-24 07:47:03PALBOCICLIB FOR HORMONE-RECEPTOR POSITIVE, HER2-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2026/02/ART17.2.png1030700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-17 09:13:392026-02-17 09:13:39TRASTUZUMAB DERUXTECAN PLUS PERTUZUMAB FOR HER2-POSITIVE METASTATIC BREAST CANCER
https://www.aigom.it/wp-content/uploads/2026/02/ART10.2-1.png1154700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-10 08:09:292026-02-10 08:14:33IMMUNE CHECKPOINT INHIBITORS FOR MISMATCH REPAIR-DEFICIENT GASTROESOPHAGEAL ADENOCARCINOMA: OUTCOMES AND FEASIBILITY OF NONOPERATIVE MANAGEMENT AT MAYO CLINIC.
https://www.aigom.it/wp-content/uploads/2026/02/ART3.2.png1172700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-03 08:31:362026-02-03 08:31:36ADJUVANT EPIRUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY TAXANES WITH OR WITHOUT CARBOPLATIN IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER (RJBC 1501): A RANDOMIZED PHASE III TRIAL.
